Acute Myeloid Leukaemia Trials; Long-term follow-up, analysis and reporting

Research output

Research output per year 2006 2006 2009 2010 2011

• 14 Article
• 1 Review article

Research output per year

Research output per year

Search results

• 2011

  Results of a randomized trial in children with Acute Myeloid Leukaemia : Medical Research Council AML12 trial

  United Kingdom Childhood Leukaemia Working Group & Dutch Childhood Oncology Group, Nov 2011, In: British Journal of Haematology. 155, 3, p. 366–376

  Research output: Contribution to journal › Article › peer-review

  • Biomedical Research 100%
  • Acute Myeloid Leukemia 94%
  • Mitoxantrone 64%
  • Confidence Intervals 59%
  • Cytarabine 56%
  136 Citations (Scopus)
• 2010

  Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol

  van der Velden, VHJ., van der Sluijs-Geling, A., Gibson, BES., Marvelde, JGT., Hoogeveen, PG., Hop, WCJ., Wheatley, K., Bierings, MB., Schuurhuis, GJ., de Graaf, SSN., van Wering, ER. & van Dongen, JJM., 1 Sept 2010, In: Leukemia. 24, 9, p. 1599-1606 8 p.

  Research output: Contribution to journal › Article

  • Residual Neoplasm 100%
  • Acute Myeloid Leukemia 89%
  • Pediatrics 60%
  • Drug Therapy 16%
  • Matched-Pair Analysis 12%
  107 Citations (Scopus)

• Cytogenetics of Childhood Acute Myeloid Leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12.

  Harrison, CJ., Hills, R., Moorman, AV., Grimwade, DJ., Hann, I., Webb, DK., Wheatley, K., de Graaf, SS., van den Berg, E., Burnett, AK. & Gibson, BE., 3 May 2010, In: Journal of Clinical Oncology.

  Research output: Contribution to journal › Article

  • Biomedical Research 100%
  • Cytogenetics 98%
  • Acute Myeloid Leukemia 94%
  • Karyotype 40%
  • Core Binding Factors 31%
  187 Citations (Scopus)

• Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

  Grimwade, D., Hills, RK., Moorman, AV., Walker, H., Chatters, S., Goldstone, AH., Wheatley, K., Harrison, CJ. & Burnett, AK., 1 Jul 2010, In: Blood. 116, 3, p. 354-365 12 p.

  Research output: Contribution to journal › Article

  • Cytogenetics 100%
  • Biomedical Research 71%
  • Chromosome Aberrations 68%
  • Acute Myeloid Leukemia 67%
  • Young Adult 57%
  1299 Citations (Scopus)

• The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA

  Burnett, AK., Hills, RK., Green, C., Jenkinson, S., Koo, K., Patel, Y., Guy, C., Gilkes, A., Milligan, D., Goldstone, AH., Prentice, AG., Wheatley, K., Linch, DC. & Gale, RE., 1 Feb 2010, In: Blood. 115, 5, p. 948-956 9 p.

  Research output: Contribution to journal › Article

  • All-Trans-Retinoic Acid 100%
  • Tretinoin 69%
  • Acute Myeloid Leukemia 64%
  • Mutation 57%
  • Drug Therapy 40%
  82 Citations (Scopus)
• 2009

  Attempts to Optimize Induction and Consolidation Treatment in Acute Myeloid Leukemia: Results of the MRC AML12 Trial.

  Burnett, AK., Hills, R., Milligan, D., Goldstone, AH., Prentice, AG., McMullin, MF., Duncombe, A., Gibson, B. & Wheatley, K., 28 Dec 2009, In: Journal of Clinical Oncology. 28, 4, p. 586-595 10 p.

  Research output: Contribution to journal › Article

  • Acute Myeloid Leukemia 100%
  • Cytarabine 79%
  • Daunorubicin 59%
  • Thioguanine 48%
  • Survival 38%
  151 Citations (Scopus)

• Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials.

  Wheatley, K., Brookes, C., Howman, A., Goldstone, AH., Milligan, D., Prentice, AG., Moorman, AV. & Burnett, AK., 1 Jun 2009, In: British Journal of Haematology. 145, 5, p. 598-605 8 p.

  Research output: Contribution to journal › Article

  • Financial Management 100%
  • Biomedical Research 87%
  • Acute Myeloid Leukemia 83%
  • Statistical Factor Analysis 77%
  • Leukemia 71%
  175 Citations (Scopus)

• Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy.

  Grimwade, D., Jovanovic, JV., Hills, RK., Nugent, EA., Patel, Y., Flora, R., Diverio, D., Jones, K., Aslett, H., Batson, E., Rennie, K., Angell, R., Clark, RE., Solomon, E., Lo-Coco, F., Wheatley, K. & Burnett, AK., 8 Jun 2009, In: Journal of Clinical Oncology.

  Research output: Contribution to journal › Article

  • Arsenic Trioxide 100%
  • Acute Promyelocytic Leukemia 92%
  • Residual Neoplasm 78%
  • Recurrence 42%
  • Leukemia 16%
  241 Citations (Scopus)

• Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party.

  Wheatley, K., Goldstone, AH., Littlewood, T., Hunter, A. & Burnett, AK., 1 Jun 2009, In: British Journal of Haematology. 146, 1, p. 54-63 10 p.

  Research output: Contribution to journal › Article

  • Induction Chemotherapy 100%
  • Granulocyte Colony-Stimulating Factor 89%
  • Biomedical Research 83%
  • Acute Myeloid Leukemia 79%
  • Leukemia 68%
  29 Citations (Scopus)

• The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial

  Burnett, AK., Milligan, D., Goldstone, A., Prentice, A., McMullin, MF., Dennis, M., Sellwood, E., Pallis, M., Russell, N., Hills, RK. & Wheatley, K., 1 May 2009, In: British Journal of Haematology. 145, 3, p. 318-332 15 p.

  Research output: Contribution to journal › Article

  • Myelodysplastic Syndromes 100%
  • valspodar 85%
  • Acute Myeloid Leukemia 84%
  • Daunorubicin 45%
  • Random Allocation 34%
  111 Citations (Scopus)
• 2007

  A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment

  Burnett, AK., Milligan, D., Prentice, AG., Goldstone, AH., McMullin, MF., Hills, R. & Wheatley, K., 1 Mar 2007, In: Cancer. 109, 6, p. 1114-1124 11 p.

  Research output: Contribution to journal › Article

  • Hydroxyurea 100%
  • Cytarabine 94%
  • Myelodysplastic Syndromes 93%
  • Tretinoin 84%
  • Acute Myeloid Leukemia 78%
  442 Citations (Scopus)

• FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia

  Mead, AJ., Linch, DC., Hills, R., Wheatley, K., Burnett, AK. & Gale, RE., 1 Aug 2007, In: Blood. 110, 4, p. 1262-1270 9 p.

  Research output: Contribution to journal › Article

  • fms-Like Tyrosine Kinase 3 100%
  • 3-tyrosine 96%
  • Acute Myeloid Leukemia 56%
  • Tyrosine 54%
  • Protein-Tyrosine Kinases 54%
  215 Citations (Scopus)
• 2006

  Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are beneficial: results of the MRC AML-HR randomized trial

  Milligan, D., Wheatley, K., Littlewood, T., Craig, JIO. & Burnett, AK., 15 Jun 2006, In: Blood. 107, p. 4614-4622 9 p.

  Research output: Contribution to journal › Article

  • Arabinoside 100%
  • All-Trans-Retinoic Acid 94%
  • Daunorubicin 90%
  • Etoposide 88%
  • fludarabine 82%
  101 Citations (Scopus)

• Guidelines on the management of acute meyloid leukaemia in adults

  Milligan, D., Grimwade, D., Cullis, JO., Bond, L., Swirsky, D., Craddock, C., Kell, J., Homewood, J., Campbell, K., McGinley, S., Wheatley, K. & Jackson, G., 1 Nov 2006, In: British Journal of Haematology. 135, p. 450-474 25 p.

  Research output: Contribution to journal › Review article
  118 Citations (Scopus)

• Treatment for myeloid leukemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and 12 trials

  Rao, A., Hills, R., Stiller, C., Gibson, BE., de Graaf, SS., Hann, IM., O'Marcaigh, A., Wheatley, K. & Webb, DK., 1 Mar 2006, In: British Journal of Haematology. 132, p. 576-583 8 p.

  Research output: Contribution to journal › Article
  73 Citations (Scopus)